Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

医学 拉帕蒂尼 卡培他滨 曲妥珠单抗 紫杉烷 曲妥珠单抗 内科学 肿瘤科 中期分析 帕妥珠单抗 转移性乳腺癌 人口 乳腺癌 癌症 临床试验 结直肠癌 环境卫生
作者
Véronique Dièras,David Miles,Sunil Verma,Mark D. Pegram,Manfred Welslau,José Baselga,Ian E. Krop,Kim T. Blackwell,Silke Hoersch,Jin Xu,Marjorie Green,Luca Gianni
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (6): 732-742 被引量:576
标识
DOI:10.1016/s1470-2045(17)30312-1
摘要

The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3 EMILIA study. In this report, we present a descriptive analysis of the final overall survival data from that trial.EMILIA was a randomised, international, open-label, phase 3 study of men and women aged 18 years or older with HER2-positive unresectable, locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. Enrolled patients were randomly assigned (1:1) via a hierarchical, dynamic randomisation scheme and an interactive voice response system to trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks) or control (capecitabine 1000 mg/m2 self-administered orally twice daily on days 1-14 on each 21-day cycle, plus lapatinib 1250 mg orally once daily on days 1-21). Randomisation was stratified by world region (USA vs western Europe vs or other), number of previous chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1), and disease involvement (visceral vs non-visceral). The coprimary efficacy endpoints were progression-free survival (per independent review committee assessment) and overall survival. Efficacy was analysed in the intention-to-treat population; safety was analysed in all patients who received at least one dose of study treatment, with patients analysed according to the treatment actually received. On May 30, 2012, the study protocol was amended to allow crossover from control to trastuzumab emtansine after the second interim overall survival analysis crossed the prespecified overall survival efficacy boundary. This study is registered with ClinicalTrials.gov, number NCT00829166.Between Feb 23, 2009, and Oct 13, 2011, 991 eligible patients were enrolled and randomly assigned to either trastuzumab emtansine (n=495) or capecitabine and lapatinib (control; n=496). In this final descriptive analysis, median overall survival was longer with trastuzumab emtansine than with control (29·9 months [95% CI 26·3-34·1] vs 25·9 months [95% CI 22·7-28·3]; hazard ratio 0·75 [95% CI 0·64-0·88]). 136 (27%) of 496 patients crossed over from control to trastuzumab emtansine after the second interim overall survival analysis (median follow-up duration 24·1 months [IQR 19·5-26·1]). Of those patients originally randomly assigned to trastuzumab emtansine, 254 (51%) of 495 received capecitabine and 241 [49%] of 495 received lapatinib (separately or in combination) after study drug discontinuation. In the safety population (488 patients treated with capecitabine plus lapatinib, 490 patients treated with trastuzumab emtansine), fewer grade 3 or worse adverse events occurred with trastuzumab emtansine (233 [48%] of 490) than with capecitabine plus lapatinib control treatment (291 [60%] of 488). In the control group, the most frequently reported grade 3 or worse adverse events were diarrhoea (103 [21%] of 488 patients) followed by palmar-plantar erythrodysaesthesia syndrome (87 [18%]), and vomiting (24 [5%]). The safety profile of trastuzumab emtansine was similar to that reported previously; the most frequently reported grade 3 or worse adverse events in the trastuzumab emtansine group were thrombocytopenia (70 [14%] of 490), increased aspartate aminotransferase levels (22 [5%]), and anaemia (19 [4%]). Nine patients died from adverse events; five of these deaths were judged to be related to treatment (two in the control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansine group [metabolic encephalopathy, neutropenic sepsis, and acute myeloid leukaemia]).This descriptive analysis of final overall survival in the EMILIA trial shows that trastuzumab emtansine improved overall survival in patients with previously treated HER2-positive metastatic breast cancer even in the presence of crossover treatment. The safety profile was similar to that reported in previous analyses, reaffirming trastuzumab emtansine as an efficacious and tolerable treatment in this patient population.F Hoffmann-La Roche/Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
森林完成签到,获得积分10
刚刚
WJ完成签到,获得积分20
1秒前
江沅完成签到,获得积分10
1秒前
小超超发布了新的文献求助10
1秒前
1秒前
敏感的盼夏完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
Philiadddd发布了新的文献求助30
2秒前
3秒前
Owen应助Kombate采纳,获得10
4秒前
4秒前
4秒前
WJ发布了新的文献求助10
5秒前
研友_8op5gL发布了新的文献求助10
5秒前
wyx完成签到,获得积分10
7秒前
甜甜玫瑰发布了新的文献求助10
8秒前
SciGPT应助宋宋采纳,获得10
8秒前
帕荣荣发布了新的文献求助10
8秒前
ZLY发布了新的文献求助10
9秒前
9秒前
huhu发布了新的文献求助10
10秒前
852应助科研通管家采纳,获得10
10秒前
大模型应助科研通管家采纳,获得10
10秒前
脑洞疼应助科研通管家采纳,获得10
10秒前
FashionBoy应助科研通管家采纳,获得10
11秒前
11秒前
深情安青应助科研通管家采纳,获得10
11秒前
Ava应助科研通管家采纳,获得10
11秒前
李爱国应助小韩采纳,获得10
11秒前
Akim应助科研通管家采纳,获得10
11秒前
SciGPT应助科研通管家采纳,获得10
11秒前
所所应助科研通管家采纳,获得10
11秒前
Hello应助科研通管家采纳,获得10
11秒前
深情安青应助科研通管家采纳,获得10
11秒前
11秒前
科研通AI5应助科研通管家采纳,获得10
11秒前
wanci应助科研通管家采纳,获得10
11秒前
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975814
求助须知:如何正确求助?哪些是违规求助? 3520123
关于积分的说明 11201020
捐赠科研通 3256502
什么是DOI,文献DOI怎么找? 1798347
邀请新用户注册赠送积分活动 877523
科研通“疑难数据库(出版商)”最低求助积分说明 806417